Download pdf
Current development and trends of cancer immunotherapy
- 1 College of Pharmacy, Changchun University of Chinese Medicine, Changchun, China
* Author to whom correspondence should be addressed.
Abstract
Normally, Tumor cells are able to evade the body's immune system and stifle it using a variety of tactics, which enables them to endure through every phase of the immunological reaction against the tumor. This is because the immune system is capable of identifying and eliminating tumor cells within the tumor microenvironment. This article describes current and future trends in cancer treatment and cancer immunotherapy, as well as the specific processes that occur in the cancer immune cycle. A class of disorders known as cancer is distinguished by aberrant cell division and invasion potential. Cancer immunotherapy has shown immense potential and possibilities in recent years, and its research has grown increasingly focused due to advancements in science and technology. The host organism's immune system generates anticancer defences during tumour development through various progressive and combinatorial mechanisms hence the term cancer-immunity cycle. The aim of this article is to describe the basic process of the cancer immune cycle as well as the various immunotherapies that are commonly used in the clinical setting today, as well as trends and future prospects. This review discusses adoptive cell transfer, cytokine therapy, cancer vaccinations, oncolytic viral treatments, and immune checkpoint inhibitors.
Keywords
Cancer, immunotherapy, immune cycle
[1]. Von Rueden SK, Fan TM. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Front Oncol. 2021 Nov 19;11:773420.
[2]. Fu Y, Tang R, Zhao X. Engineering cytokines for cancer immunotherapy: a systematic review. Front Immunol. 2023 Jul 6;14:1218082.
[3]. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807-821.
[4]. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023 Oct 10;56(10):2188-2205.
[5]. Igarashi Y, Sasada T. Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. J Immunol Res. 2020 Nov 17;2020:5825401.
[6]. Abbott M, Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. 2019 Oct;35(5):150923.
[7]. Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023 Feb;9(2):122-139.
[8]. Zhang li.(2020).A critical review of 200 cases of adverse reactions associated with immune checkpoint inhibitors. Peking: Tsinghua University Press
[9]. Fu Y, Tang R, Zhao X. Engineering cytokines for cancer immunotherapy: a systematic review. Front Immunol. 2023 Jul 6;14:1218082.
[10]. Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12.
[11]. Cheng Yuwei, Yang Feng, Zhang Yunchang. Research progress of phototherapy combined with immune checkpoint inhibitors in the treatment of tumors. Chinese Journal of Cancer Biotherapy.2024 Jul 31;06:626-631.
Cite this article
Li,Y. (2024). Current development and trends of cancer immunotherapy. Theoretical and Natural Science,54,95-99.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Workshop on Intelligent Medical Data Analysis for Precision Medicine
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).